Related references
Note: Only part of the references are listed.Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence
Cihangir Duy et al.
CANCER DISCOVERY (2021)
Sequential CRISPR gene editing in human iPSCs charts the clonal evolution of myeloid leukemia and identifies early disease targets
Tiansu Wang et al.
CELL STEM CELL (2021)
Dimeric Structure of the Pseudokinase IRAK3 Suggests an Allosteric Mechanism for Negative Regulation
Sven M. Lange et al.
STRUCTURE (2021)
Inhibition of IRAK1/4 enhances the antitumor effect of lenvatinib in anaplastic thyroid cancer cells
Yoshifumi Kawamura et al.
CANCER SCIENCE (2021)
Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS
Jennifer J. Trowbridge et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2021)
Discovery of Highly Potent and Selective IRAK1 Degraders to Probe Scaffolding Functions of IRAK1 in ABC DLBCL
Liqiang Fu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
SMARCA4 oncogenic potential via IRAK1 enhancer to activate Gankyrin and AKR1B10 in liver cancer
Sang Yean Kim et al.
ONCOGENE (2021)
Therapeutic targeting of the inflammasome in myeloid malignancies
Samarpana Chakraborty et al.
BLOOD CANCER JOURNAL (2021)
Targeting Interleukin-1 Receptor-Associated Kinase 1 (IRAK1) In Ovarian Cancer
Nipam Raval et al.
FASEB JOURNAL (2021)
Altered expression of microRNA-92b-3p predicts survival outcomes of patients with prostate cancer and functions as an oncogene in tumor progression
Gang Wang et al.
ONCOLOGY LETTERS (2021)
Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML
Jae Yoon Jeon et al.
INVESTIGATIONAL NEW DRUGS (2020)
Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia
Neus Gimenez et al.
LEUKEMIA (2020)
Neutrophils Deficient in Innate Suppressor IRAK-M Enhances Anti-tumor Immune Responses
Yao Zhang et al.
MOLECULAR THERAPY (2020)
MyD88 Death-Domain Oligomerization Determines Myddosome Architecture: Implications for Toll-like Receptor Signaling
Martin C. Moncrieffe et al.
STRUCTURE (2020)
Glucocorticoids enhance the antileukemic activity of FLT3 inhibitors in FLT3-mutant acute myeloid leukemia
Melat T. Gebru et al.
BLOOD (2020)
Targeting AML-associated FLT3 mutations with a type I kinase inhibitor
LaQuita M. Jones et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation
Shaima'a Hamarsheh et al.
NATURE COMMUNICATIONS (2020)
The Nlrp3 inflammasome as a rising star in studies of normal and malignant hematopoiesis
Mariusz Z. Ratajczak et al.
LEUKEMIA (2020)
Adaptive response to inflammation contributes to sustained myelopoiesis and confers a competitive advantage in myelodysplastic syndrome HSCs
Tomoya Muto et al.
NATURE IMMUNOLOGY (2020)
Contribution of Aberrant Toll Like Receptor Signaling to the Pathogenesis of Myelodysplastic Syndromes
Luana Chiquetto Paracatu et al.
FRONTIERS IN IMMUNOLOGY (2020)
TPL2 enforces RAS-induced inflammatory signaling and is activated by point mutations
Paarth B. Dodhiawala et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
S100A14 suppresses metastasis of nasopharyngeal carcinoma by inhibition of NF-kB signaling through degradation of IRAK1
Dong-Fang Meng et al.
ONCOGENE (2020)
Discovery of Proteolysis-Targeting Chimera Molecules that Selectively Degrade the IRAK3 Pseudokinase
Sebastien L. Degorce et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Myelodysplastic Syndromes
Mario Cazzola
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Discovery of a Selective, Covalent IRAK1 Inhibitor with Antiproliferative Activity in MYD88 Mutated B-Cell Lymphoma
John M. Hatcher et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
miR-146b-5p Enhances the Sensitivity of NSCLC to EGFR Tyrosine Kinase Inhibitors by Regulating the IRAK1/NF-κB Pathway
Yi-Nan Liu et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2020)
Targeting MYD88-Mutant DLBCL with IRAKIMiDs: A Comparison to IRAK4 Kinase Inhibition and Evaluation of Synergy with Rational Combinations
Jennifer Kimberly Lue et al.
BLOOD (2020)
Safety, Pharmacokinetics and Activity of CA-4948, an IRAK4 Inhibitor, for Treatment of Patients with Relapsed or Refractory Hematologic Malignancies: Results from the Phase 1 Study
Grzegorz S. Nowakowski et al.
BLOOD (2020)
Assessing IRAK4 Functions in ABC DLBCL by IRAK4 Kinase Inhibition and Protein Degradation
Jing Zhang et al.
CELL CHEMICAL BIOLOGY (2020)
Significant Association Between the MiR146a Genotypes and Susceptibility to Childhood Acute Lymphoblastic Leukemia in Taiwan
Jen-Sheng Pei et al.
CANCER GENOMICS & PROTEOMICS (2020)
The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes
David A. Sallman et al.
BLOOD (2019)
U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies
Molly A. Smith et al.
NATURE CELL BIOLOGY (2019)
Overcoming adaptive therapy resistance in AML by targeting immune response pathways
Katelyn Melgar et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
SF3B1 Mutations Induce Oncogenic IRAK4 Isoforms and Activate Targetable Innate Immune Pathways in MDS and AML
Gaurav S. Choudhary et al.
BLOOD (2019)
The Oral JAK2/IRAK1 Inhibitor Pacritinib Demonstrates Spleen Volume Reduction in Myelofibrosis Patients Independent of JAK2V617F Allele Burden
Srdan Verstovsek et al.
BLOOD (2019)
IRAK3 modulates downstream innate immune signalling through its guanylate cyclase activity
L. A. Freihat et al.
SCIENTIFIC REPORTS (2019)
MYD88 L265P mutations identify a prognostic gene expression signature and a pathway for targeted inhibition in CLL
Ma. Reina Improgo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib
Eman L. Dadashian et al.
CANCER RESEARCH (2019)
An IRAK1-PIN1 signalling axis drives intrinsic tumour resistance to radiation therapy
Peter H. Liu et al.
NATURE CELL BIOLOGY (2019)
IRAK4 mediates colitis-induced tumorigenesis and chemoresistance in colorectal cancer
Qiong Li et al.
JCI INSIGHT (2019)
Tumor-Stroma IL1 beta-IRAK4 Feedforward Circuitry DrivesTumor Fibrosis, Chemoresistance, and Poor Prognosis in Pancreatic Cancer
Daoxiang Zhang et al.
CANCER RESEARCH (2018)
IRAK1 Augments Cancer Stemness and Drug Resistance via the AP-1/AKR1B10 Signaling Cascade in Hepatocellular Carcinoma
Bowie Y. Cheng et al.
CANCER RESEARCH (2018)
IRAK2 counterbalances oncogenic Smurf1 in colon cancer cells by dictating ER stress
Jingwen Liu et al.
CELLULAR SIGNALLING (2018)
Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer
Yinghui Xu et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Expression of microRNAs and IRAK1 pathway genes are altered in gastric cancer patients with Helicobacter pylori infection
Reza Ranjbar et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2018)
Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes
Mona M. Hosseini et al.
LEUKEMIA (2018)
A multiprotein supercomplex controlling oncogenic signalling in lymphoma
James D. Phelan et al.
NATURE (2018)
The E3 ubiquitin ligase Pellino2 mediates priming of the NLRP3 inflammasome
Fiachra Humphries et al.
NATURE COMMUNICATIONS (2018)
Disordered Immune Regulation and its Therapeutic Targeting in Myelodysplastic Syndromes
Kathryn S. Ivy et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2018)
Cytokine production by activated plasmacytoid dendritic cells and natural killer cells is suppressed by an IRAK4 inhibitor
Karin Hjorton et al.
ARTHRITIS RESEARCH & THERAPY (2018)
Preclinical Activity of IRAK4 Kinase Inhibitor CA-4948 Alone or in Combination with Targeted Therapies and Preliminary Phase 1 Clinical Results in Non-Hodgkin Lymphoma
Robert N. Booher et al.
BLOOD (2018)
Chronic immune response dysregulation in MDS pathogenesis
Laura Barreyro et al.
BLOOD (2018)
Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma
Daoxiang Zhang et al.
CLINICAL CANCER RESEARCH (2017)
Epistasis between TIFAB and miR-146a: neighboring genes in del(5q) myelodysplastic syndrome
M. E. Varney et al.
LEUKEMIA (2017)
Ubiquitination of hnRNPA1 by TRAF6 links chronic innate immune signaling with myelodysplasia
Jing Fang et al.
NATURE IMMUNOLOGY (2017)
Sensitizing leukemia stem cells to NF-κB inhibitor treatment in vivo by inactivation of both TNF and IL-1 signaling
Jing Li et al.
ONCOTARGET (2017)
Tet2 restrains inflammatory gene expression in macrophages
Alyssa H. Cull et al.
EXPERIMENTAL HEMATOLOGY (2017)
IRAK4 kinase activity controls Toll-like receptor-induced inflammation through the transcription factor IRF5 in primary human monocytes
Leah Cushing et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88L265P Diffuse Large B-Cell Lymphoma
James S. Scott et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Chromosome 1q21.3 amplification is a trackable biomarker and actionable target for breast cancer recurrence
Jian Yuan Goh et al.
NATURE MEDICINE (2017)
Crystal structure of human IRAK1
Li Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Diagnostic and prognostic roles of IRAK1 in hepatocellular carcinoma tissues: an analysis of immunohistochemistry and RNA-sequencing data from the cancer genome atlas
Zhi-hua Ye et al.
ONCOTARGETS AND THERAPY (2017)
Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia
Alyssa Carey et al.
CELL REPORTS (2017)
IRAK2 directs stimulus-dependent nuclear export of inflammatory mRNAs
Hao Zhou et al.
ELIFE (2017)
Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma
Anupama Reddy et al.
CELL (2017)
The mechanism of activation of IRAK1 and IRAK4 by interleukin-1 and Toll-like receptor agonists
Stefan Vollmer et al.
BIOCHEMICAL JOURNAL (2017)
Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome
Astrid Olsnes Kittang et al.
ONCOIMMUNOLOGY (2016)
The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype
Ashley A. Basiorka et al.
BLOOD (2016)
Mesenchymal Inflammation Drives Genotoxic Stress in Hematopoietic Stem Cells and Predicts Disease Evolution in Human Pre-leukemia
Noemi A. Zambetti et al.
CELL STEM CELL (2016)
Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9
Rebekka K. Schneider et al.
NATURE MEDICINE (2016)
Comprehensive RNAi-based screening of human and mouse TLR pathways identifies species-specific preferences in signaling protein use
Jing Sun et al.
SCIENCE SIGNALING (2016)
Mechanism and Regulation of NLRP3 Inflammasome Activation
Yuan He et al.
TRENDS IN BIOCHEMICAL SCIENCES (2016)
Comprehensive RNAi-based screening of human and mouse TLR pathways identifies species-specific preferences in signaling protein use
Jing Sun et al.
SCIENCE SIGNALING (2016)
The Role of Toll-Like Receptors in Hematopoietic Malignancies
Darlene A. Monlish et al.
FRONTIERS IN IMMUNOLOGY (2016)
Unraveling the Pathogenesis of MDS: The NLRP3 inflammasome and Pyroptosis Drive the MDS Phenotype
David A. Sallman et al.
FRONTIERS IN ONCOLOGY (2016)
Deconstructing innate immune signaling in myelodysplastic syndromes
Melinda E. Varney et al.
EXPERIMENTAL HEMATOLOGY (2015)
Toll-like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation
Eleonora Fonte et al.
HAEMATOLOGICA (2015)
Inhibition of IRAK1/4 sensitizes T cell acute lymphoblastic leukemia to chemotherapies
Zhaoyang Li et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor-TRAF6 signaling
Melinda E. Varney et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes
I. Ganan-Gomez et al.
LEUKEMIA (2015)
Methylation of IRAK3 is a novel prognostic marker in hepatocellular carcinoma
Chih-Chi Kuo et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel
Zhen Ning Wee et al.
NATURE COMMUNICATIONS (2015)
Targeting IRAK1 in T-Cell acute lymphoblastic leukemia
Charles Dussiau et al.
ONCOTARGET (2015)
IRAK1 is a novel DEK transcriptional target and is essential for head and neck cancer cell survival
Allie K. Adams et al.
ONCOTARGET (2015)
Toll-like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation
Eleonora Fonte et al.
HAEMATOLOGICA (2015)
Whole-genome integrative analysis reveals expression signatures predicting transformation in follicular lymphoma
Marianne Brodtkorb et al.
BLOOD (2014)
Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome
Alejandra Martinez-Trillos et al.
BLOOD (2014)
The structure function of the death domain of human IRAK-M
Jiangfeng Du et al.
CELL COMMUNICATION AND SIGNALING (2014)
A Coding IRAK2 Protein Variant Compromises Toll-like receptor (TLR) Signaling and Is Associated with Colorectal Cancer Survival
Hui Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
IRAK4 Dimerization and trans-Autophosphorylation Are Induced by Myddosome Assembly
Ryan Ferrao et al.
MOLECULAR CELL (2014)
IRAK-1 bypasses priming and directly links TLRs to rapid NLRP3 inflammasome activation
Keng-Mean Lin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Interleukin 1 receptor-associated kinase 1 (IRAK1) mutation is a common, essential driver for Kaposi sarcoma herpesvirus lymphoma
Dongmei Yang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Myeloid Malignancies with Chromosome 5q Deletions Acquire a Dependency on an Intrachromosomal NF-κB Gene Network
Jing Fang et al.
CELL REPORTS (2014)
MYD88 L265P mutation in Waldenstrom macroglobulinemia
Stephanie Poulain et al.
BLOOD (2013)
Targeting IRAK1 as a Therapeutic Approach for Myelodysplastic Syndrome
Garrett W. Rhyasen et al.
CANCER CELL (2013)
Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia
Dan A. Landau et al.
CELL (2013)
IRAK-M mediates Toll-like receptor/IL-1R-induced NFκB activation and cytokine production
Hao Zhou et al.
EMBO JOURNAL (2013)
Induction of myelodysplasia by myeloid-derived suppressor cells
Xianghong Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo
Omar Abdel-Wahab et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Cutting Edge: TLR Signaling Licenses IRAK1 for Rapid Activation of the NLRP3 Inflammasome
Teresa Fernandes-Alnemri et al.
JOURNAL OF IMMUNOLOGY (2013)
Two Phases of Inflammatory Mediator Production Defined by the Study of IRAK2 and IRAK1 Knock-in Mice
Eduardo Pauls et al.
JOURNAL OF IMMUNOLOGY (2013)
Toll-like receptor alterations in myelodysplastic syndrome
Y. Wei et al.
LEUKEMIA (2013)
Overexpression of the Toll-Like Receptor (TLR) Signaling Adaptor MYD88, but Lack of Genetic Mutation, in Myelodysplastic Syndromes
Sophie Dimicoli et al.
PLOS ONE (2013)
Activation of the canonical IKK complex by K63/M1-linked hybrid ubiquitin chains
Christoph H. Emmerich et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Augmentation of Therapeutic Responses in Melanoma by Inhibition of IRAK-1,-4
Ratika Srivastava et al.
CANCER RESEARCH (2012)
MYD88 L265P Somatic Mutation in Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Triggering of toll-like receptor-4 in human multiple myeloma cells promotes proliferation and alters cell responses to immune and chemotherapy drug attack
Hanying Bao et al.
CANCER BIOLOGY & THERAPY (2011)
Oncogenically active MYD88 mutations in human lymphoma
Vu N. Ngo et al.
NATURE (2011)
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
Xose S. Puente et al.
NATURE (2011)
TGF-β-induced IRAK-M expression in tumor-associated macrophages regulates lung tumor growth
T. J. Standiford et al.
ONCOGENE (2011)
NF-κB dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies
Jimmy L. Zhao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Expression of Interleukin-1 Receptor-Associated Kinase-1 in Non-Small Cell Lung Carcinoma and Preneoplastic Lesions
Carmen Behrens et al.
CLINICAL CANCER RESEARCH (2010)
Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells
A. Pellagatti et al.
LEUKEMIA (2010)
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
R. Eric Davis et al.
NATURE (2010)
Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling
Su-Chang Lin et al.
NATURE (2010)
Identification of miR-145 and miR-146a as mediators of the 5q-syndrome phenotype
Daniel T. Starczynowski et al.
NATURE MEDICINE (2010)
Expression of Toll-Like Receptor-9 Is Increased in Poorly Differentiated Prostate Tumors
Marja-Riitta Vaisanen et al.
PROSTATE (2010)
Interleukin-1 Receptor-associated Kinase 2 Is Critical for Lipopolysaccharide-mediated Post-transcriptional Control
Youzhong Wan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
The kinase activities of interleukin-1 receptor associated kinase (IRAK)-1 and 4 are redundant in the control of inflammatory cytokine expression in human cells
Kyung W. Song et al.
MOLECULAR IMMUNOLOGY (2009)
Induction of a Chronic Disease State in Patients With Smoldering or Indolent Multiple Myeloma by Targeting Interleukin 1β-Induced Interleukin 6 Production and the Myeloma Proliferative Component
John A. Lust et al.
MAYO CLINIC PROCEEDINGS (2009)
Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein
Pingyan Cheng et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells
Pratima Sinha et al.
JOURNAL OF IMMUNOLOGY (2008)
Lys63-linked polyubiquitination of IRAK-1 is required for interleukin-1 receptor- and Toll-like receptor-mediated NF-κB activation
Dietrich B. Conze et al.
MOLECULAR AND CELLULAR BIOLOGY (2008)
Sequential control of Toll-like receptor-dependent responses by IRAK1 and IRAK2
Tatsukata Kawagoe et al.
NATURE IMMUNOLOGY (2008)
IRAK-2 participates in multiple toll-like receptor signaling pathways to NFκB via activation of TRAF6 ubiquitination
Sinead E. Keating et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Induction of IRAK-M is associated with lipopolysaccharide tolerance in a human endotoxemia model
Cornelis van 't Veer et al.
JOURNAL OF IMMUNOLOGY (2007)
IRAK-M is involved in the pathogenesis of early-onset persistent asthma
Lenuta Balaci et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2007)
The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling
Luke A. J. O'Neill et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Toll-like receptor-4 is up-regulated in hematopoietic progenitor cells and contributes to increased apoptosis in myelodysplastic syndromes
Christos I. Maratheftis et al.
CLINICAL CANCER RESEARCH (2007)
Opinion - Toll-like receptors as molecular switches
Nicholas J. Gay et al.
NATURE REVIEWS IMMUNOLOGY (2006)
Tumor cells deactivate human monocytes by up-regulating IL-1 receptor associated kinase-M expression via CD44 and TLR4
C del Fresno et al.
JOURNAL OF IMMUNOLOGY (2005)
Sequential autophosphorylation steps in the interleukin-1 receptor-associated kinase-1 regulate its availability as an adapter in interleukin-1 signaling
C Kollewe et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Identification and cloning of genes displaying elevated expression as a consequence of metastatic progression in human melanoma cells by rapid subtraction hybridization
H Boukerche et al.
GENE (2004)
IRAK4 kinase activity is redundant for interleukin-1 (IL-1) receptor-associated kinase phosphorylation and IL-1 responsiveness
JZ Qin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members
S Janssens et al.
MOLECULAR CELL (2003)
Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow
WK Hofmann et al.
BLOOD (2002)
Summary and comparison of the signaling mechanisms of the Toll/interleukin-1 receptor family
MU Martin et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2002)
IRAK-M is a negative regulator of toll-like receptor signaling
K Kobayashi et al.
CELL (2002)
Distinct molecular mechanism for initiating TRAF6 signalling
H Ye et al.
NATURE (2002)
IRAK-4: A novel member of the IRAK family with the properties of an IRAK-kinase
SY Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Share Paper
